Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
暂无分享,去创建一个
Deepak L. Bhatt | J. Tardif | C. Ballantyne | T. A. Jacobson | P. Steg | Michael Miller | E. Brinton | R. Juliano | C. Granowitz | S. Ketchum | L. Jiao | R. Doyle | T. Jacobson
[1] A. Ferro,et al. Changes in C-reactive protein in response to anti-inflammatory therapy as a predictor of cardiovascular outcomes: A systematic review and meta-analysis , 2020, JRSM cardiovascular disease.
[2] J. Borén,et al. Causes and Consequences of Hypertriglyceridemia , 2020, Frontiers in Endocrinology.
[3] N. Wong,et al. The Evolving Understanding and Approach to Residual Cardiovascular Risk Management , 2020, Frontiers in Cardiovascular Medicine.
[4] A. Wierzbicki,et al. The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease , 2020, Therapeutic advances in chronic disease.
[5] K. Reynolds,et al. Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin‐controlled LDL cholesterol , 2018, Diabetes, obesity & metabolism.
[6] Odyssey Outcomes Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome , 2018 .
[7] R. Collins,et al. Effects of n‐3 Fatty Acid Supplements in Diabetes Mellitus , 2018, The New England journal of medicine.
[8] D. Mozaffarian,et al. Assessment of omega‐3 carboxylic acids in statin‐treated patients with high levels of triglycerides and low levels of high‐density lipoprotein cholesterol: Rationale and design of the STRENGTH trial , 2018, Clinical cardiology.
[9] P. Toth,et al. High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real‐World Administrative Claims Analysis of Statin‐Treated Patients With High Residual Cardiovascular Risk , 2018, Journal of the American Heart Association.
[10] Deepak L. Bhatt,et al. Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management. , 2018, Journal of the American College of Cardiology.
[11] K. Reynolds,et al. Increased Cardiovascular Risk in Hypertriglyceridemic Patients With Statin-Controlled LDL Cholesterol , 2018, The Journal of clinical endocrinology and metabolism.
[12] R. Mason,et al. Eicosapentaenoic acid and docosahexaenoic acid have distinct membrane locations and lipid interactions as determined by X-ray diffraction. , 2018, Chemistry and physics of lipids.
[13] R. Collins,et al. Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks , 2018, JAMA cardiology.
[14] J. Chang,et al. Safety and tolerability of prescription omega-3 fatty acids: A systematic review and meta-analysis of randomized controlled trials. , 2018, Prostaglandins, leukotrienes, and essential fatty acids.
[15] Deepak L. Bhatt,et al. Primary Prevention of Atherosclerosis: Time to Take a Selfie? , 2017, Journal of the American College of Cardiology.
[16] I. Kubota,et al. A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins. , 2017, Journal of cardiology.
[17] Deepak L. Bhatt,et al. CANTOS Ushers in a New Calculus of Inflammasome Targeting for Vascular Protection-and Maybe More. , 2017, Cell metabolism.
[18] Deepak L. Bhatt,et al. How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD. , 2017, Journal of the American College of Cardiology.
[19] P. Libby,et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.
[20] M. Budoff,et al. Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients with Elevated Triglycerides(200-499mg/dL)on Statin Therapy(EVAPORATE Study): Rationale and Design , 2017 .
[21] M. Budoff,et al. Potential benefits of eicosapentaenoic acid on atherosclerotic plaques. , 2017, Vascular pharmacology.
[22] Deepak L. Bhatt,et al. Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial , 2017, Clinical cardiology.
[23] S. Shrivastava,et al. Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes. , 2016, Biochimica et biophysica acta.
[24] C. Ballantyne,et al. Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies. , 2016, Prostaglandins & other lipid mediators.
[25] A. Tenenbaum,et al. Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease: Twenty-Two–Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry , 2016, Circulation. Cardiovascular quality and outcomes.
[26] Deepak L. Bhatt,et al. Moving Toward Global Primordial Prevention in Cardiovascular Disease: The Heart of the Matter. , 2015, Journal of the American College of Cardiology.
[27] K. Borow,et al. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. , 2015, Atherosclerosis.
[28] Improve-It Investigators. Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .
[29] P. Libby. Triglycerides on the rise: should we swap seats on the seesaw? , 2015, European heart journal.
[30] Hiroshi Ito,et al. Early eicosapentaenoic acid treatment after percutaneous coronary intervention reduces acute inflammatory responses and ventricular arrhythmias in patients with acute myocardial infarction: a randomized, controlled study. , 2014, International journal of cardiology.
[31] Deepak L. Bhatt,et al. Antiplatelet and Anticoagulation Therapy for Acute Coronary Syndromes , 2014, Circulation research.
[32] M. Blaha,et al. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. , 2013, JAMA.
[33] C. Ballantyne,et al. Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies , 2013, American Journal of Cardiovascular Drugs.
[34] C. Ballantyne,et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). , 2012, The American journal of cardiology.
[35] S. Yusuf,et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. , 2012, The New England journal of medicine.
[36] C. Ballantyne,et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). , 2011, The American journal of cardiology.
[37] Y. Matsuzawa,et al. Relationships between plasma fatty acid composition and coronary artery disease. , 2011, Journal of atherosclerosis and thrombosis.
[38] Deepak L. Bhatt,et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. , 2010, JAMA.
[39] Y. Matsuzawa,et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis , 2007, The Lancet.
[40] J. LeLorier,et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.
[41] D G Altman,et al. Confidence intervals for the number needed to treat , 1998, BMJ.
[42] L E Daly,et al. Confidence limits made easy: interval estimation using a substitution method. , 1998, American journal of epidemiology.